Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.44 +2.5%	$2.50	$1.28 ▼ $7.85	$267.70M	1.3	1.12 million shs	2.66 million shs
FHTX Foghorn Therapeutics	$4.98 -3.1%	$5.20	$2.94 ▼ $10.25	$281.52M	3.05	110,714 shs	55,948 shs
GLUE Monte Rosa Therapeutics	$4.58 +5.3%	$4.97	$3.50 ▼ $12.40	$282.86M	1.42	436,530 shs	535,084 shs
ZIVO ZIVO Bioscience	$18.25 +0.2%	$13.73	$6.50 ▼ $22.15	$69.66M	-0.06	1,059 shs	2,556 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	+3.39%	+4.27%	+21.39%	-56.51%
FHTX Foghorn Therapeutics	0.00%	+8.73%	-18.36%	+12.42%	-11.07%
GLUE Monte Rosa Therapeutics	0.00%	+4.57%	-22.37%	+15.08%	+1.78%
ZIVO ZIVO Bioscience	0.00%	+25.95%	+37.74%	+1.39%	+112.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	3.1614 of 5 stars	3.5	3.0	3.1	2.5	0.6
FHTX Foghorn Therapeutics	2.9103 of 5 stars	3.6	3.0	2.8	1.7	0.6
GLUE Monte Rosa Therapeutics	2.8249 of 5 stars	3.3	1.0	2.7	1.7	1.9
ZIVO ZIVO Bioscience	0.2479 of 5 stars	0.0	3.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	3.00	Buy	$12.50	412.30% Upside
FHTX Foghorn Therapeutics	3.14	Buy	$12.00	140.96% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	234.79% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIVO, GLUE, FHTX, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$2.75 per share	N/A
FHTX Foghorn Therapeutics	$24.17M	11.65	N/A	N/A	($1.36) per share	-3.66
GLUE Monte Rosa Therapeutics	$177.99M	1.59	N/A	N/A	$4.34 per share	1.06
ZIVO ZIVO Bioscience	$15.85K	4,394.97	N/A	N/A	($0.81) per share	-22.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.29	N/A	N/A	N/A	N/A	-64.57%	-54.35%	N/A
FHTX Foghorn Therapeutics	-$86.62M	-$1.19	N/A	N/A	N/A	-311.90%	N/A	-28.00%	11/3/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.36	12.72	N/A	N/A	13.58%	9.95%	6.42%	N/A
ZIVO ZIVO Bioscience	-$7.78M	-$4.93	N/A	∞	N/A	N/A	N/A	-2,240.92%	N/A

Latest ZIVO, GLUE, FHTX, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/7/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	-$0.15	+$0.16	-$0.15	$7.23 million	$23.19 million
8/5/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$7.62 million	$7.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	7.99	7.99
FHTX Foghorn Therapeutics	N/A	2.62	2.62
GLUE Monte Rosa Therapeutics	N/A	7.16	5.61
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
FHTX Foghorn Therapeutics	61.55%
GLUE Monte Rosa Therapeutics	79.96%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	11.87%
FHTX Foghorn Therapeutics	7.58%
GLUE Monte Rosa Therapeutics	6.90%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.71 million	96.69 million	Optionable
FHTX Foghorn Therapeutics	120	56.53 million	52.25 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.76 million	57.50 million	Optionable
ZIVO ZIVO Bioscience	10	3.82 million	2.91 million	Not Optionable

ZIVO, GLUE, FHTX, and ANNX Headlines

Recent News About These Companies

Analyzing ZIVO Bioscience (NASDAQ:ZIVO) & Protalix BioTherapeutics (NYSE:PLX)

August 15 at 3:39 AM | americanbankingnews.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO, GLUE, FHTX, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$2.44 +0.06 (+2.52%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.44 +0.00 (+0.20%)

As of 08/15/2025 07:56 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Foghorn Therapeutics NASDAQ:FHTX

$4.98 -0.16 (-3.11%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$5.00 +0.02 (+0.40%)

As of 08/15/2025 05:10 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.58 +0.23 (+5.29%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.58 +0.00 (+0.11%)

As of 08/15/2025 07:04 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

ZIVO Bioscience NASDAQ:ZIVO

$18.25 +0.03 (+0.16%)

As of 08/15/2025 03:57 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time